Assessment Status | Assessment Process Complete |
HTA ID | 21011 |
Drug | Olaparib |
Brand | Lynparza® |
Indication | Olaparib in combination with bevacizumab is indicated for the maintenance treatment of adult patients with advanced (FIGO stages III and IV) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer who are in response (complete or partial) following completion of first-line platinum-based chemotherapy in combination with bevacizumab and whose cancer is associated with homologous recombination deficiency (HRD) positive status defined by either a BRCA1/2 mutation and/or genomic instability. |
Assessment Process | |
Rapid review commissioned | 24/03/2021 |
Rapid review completed | 28/04/2021 |
Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of olaparib in combination with bevacizumab compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE | 31/05/2021 |
Pre-submission consultation with Applicant | 04/10/2021 |
Full submission received from Applicant | 07/02/2022 |
Preliminary review sent to Applicant | 02/09/2022 |
NCPE assessment re-commenced | 11/11/2022 |
Factual accuracy sent to applicant | 12/01/2023 |
NCPE assessment re-commenced | 20/01/2023 |
NCPE assessment completed | 27/01/2023 |
NCPE assessment outcome | The NCPE recommends that olaparib in combination with bevacizumab be considered for reimbursement if cost-effectiveness can be improved relative to existing treatments* |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.